How to Improve Cytotoxic Therapy in Advanced Breast Cancer

References

• Brincker H. Distant recurrence in breast cancer. Survival expectations and first choice of chemotherapy regimen. Acta Oncol 1988; 27: 729–32
   PubMed Web of Science ®Google Scholar
• Ross M B, Buzdar A U, Smith T L, et al. Improved survival of patients with metastic breast cancer receiving combination chemotherapy. Cancer 1985; 55: 341–6
   PubMed Web of Science ®Google Scholar
• Powles T J, Coombes R C, Smith I E, Jones J M, Ford H T, Gazet J-C. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet 1980; 1: 580–2
   PubMed Web of Science ®Google Scholar
• Patel J K, Nemoto T, Vezeridis M, Petrelli N, Suh O, Dao T L. Does more intense palliative treatment improve overall survival in metastatic breast cancer patients. Cancer 1986; 57: 567–70
   PubMed Web of Science ®Google Scholar
• Todd Shofag M. M, Cadman E. Survival of women with metastatic breast cancer at Yale from 1920 to 1980. J Clin Oncol 1983; 1: 406–8
   Google Scholar
• Coates A, Gebski V, Bishop J F, et al. Improving the quality of life during chemotherapy for advanced breast cancer. New Engl J Med 1987; 317: 1490–5
   PubMed Web of Science ®Google Scholar
• Cantwell B. Short course mitoxantrone versus continuous chemotherapy in advanced breast cancer. Proc 2nd Nordic Novantrone Symposium, Oslo, November, 1988
   Google Scholar
• 4th EORTC Breast Cancer Working Conference, London, June, 1987
   Google Scholar
• Danish Breast Cancer Cooperative Group. DBCG, 85: R2
   Google Scholar
• Goldie J H, Goldman A J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727–33
   PubMedGoogle Scholar
• Vogel C L, Smalley R V, Raney M, et al. Randomized trial of cyclophosphamide, doxorubicin, and fluorouracil alone or alternating with a ‘cycle active’ non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group Project. J Clin Oncol 1984; 2: 643–51
   PubMed Web of Science ®Google Scholar
• Aisner J, Korzun A, Perloff M, et al. A randomized comparison of CAF, VATH and VATH alternating with CMFVP for advanced breast cancer, a CALGB study. (Abstr 27) Proc ASCO 1988
   Google Scholar
• Spittle M F, Hill B F, Ostrowski M J, et al. A randomized, prospective, comparative, multicenter trial of a single combination versus alternating combinations of antitumor drugs in advanced breast cancer. Eur J Cancer Clin Oncol 1987; 23: 1155–62
   Google Scholar
• Tormey D, Gelman R, Falkson G. Prospective evaluation of rotating chemotherapy in advanced breast cancer. Am J Clin Oncol 1983; 6: 1–18
   Google Scholar
• Bruce W R, Meeker B E, Valeriote F A. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. JNCI 1966; 37: 233–45
   PubMedGoogle Scholar
• Pinkel D, Hernandez D, Borella L, et al. Drug dosage and remission duration in childhood lymphatic leukemia. Cancer 1971; 39: 34–40
   Google Scholar
• Samson M K, Rivkin S E, Jones S E, et al. Dose-response and dose-survival advantages for high- versus low-dose cisplatin combined with vinblastin and bleomycin in disseminated testicular cancer. Cancer 1984; 53: 1029–35
   PubMed Web of Science ®Google Scholar
• Cohen M H, Creaven P J, Fossieck B E, Jr, et al. Intensive chemotherapy in small-cell bronchogenic carcinoma. Cancer Treat Rep 1977; 61: 349–54
   PubMedGoogle Scholar
• Hande K R, Oldham R KK, Fer M F, et al. Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small-cell lung cancer. Am J Med 1982; 73: 413–9
   PubMed Web of Science ®Google Scholar
• Figuerado A T, Hryniuk W M, Strautmanis I, et al. Cotrimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985; 3: 54–64
   Google Scholar
• Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. New Engl J Med 1981; 304: 10–5
   PubMed Web of Science ®Google Scholar
• Brufman G, Sulkes A, Fuks Z, Biran S. Cytoxan, methotrexate and 5-fluorouracil (CMF) chemotherapy in metastatic breast cancer: the influence of dose levels and performance status upon response rates and survival. Proc ASCO 1983; C-402: 103
   Google Scholar
• Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281–8
   PubMed Web of Science ®Google Scholar
• Henderson I C, Hayes D F, Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 1988; 6: 1501–15
   PubMed Web of Science ®Google Scholar
• O'Bryan R M, Baker L H, Gottlieb J E, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer 1977; 39: 1940–8
   PubMed Web of Science ®Google Scholar
• Creech R H, Catalano R B, Hopson R C. A comparison of standard-dose adriamycin and low-dose adriamycin as primary chemotherapy for metastatic breast cancer. Proc AACR 1980; 566: 142
   Google Scholar
• Carmo-Pereira J, Oliveira Costa F, Henriques E, et al. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 1987; 56: 471–3
   PubMed Web of Science ®Google Scholar
• Ebbs S R, Graham H, A'Hern R P, Bates T, Baum M. Aprospective randomized trial comparing low and high dose epirubicin given as either bolus injection or prolonged infusion for advanced breast cancer. Proc. 3rd Scandinavian Breast Cancer Symposium, Örenäs, 1988, 13
   Google Scholar
• Becher R, Kurschel E, Kleke O, et al. Randomized study of epirubicin and cyclophosphamide in advanced breast cancer. Proc ASCO 1988; 125: 32
   Google Scholar
• Hortobagyi G, Bodey G P, Buzdar A U, et al. Evaluation of highdose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol 1987; 5: 354–64
   PubMed Web of Science ®Google Scholar
• Tannock I F, Boyd N F, DeBoer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377–87
   PubMed Web of Science ®Google Scholar
• Beretta G, Tabiadon D, Tedeschi L, Gambrosier P, Beretta G D, Luporini G. Front-line treatment with CMF variations for advanced breast carcinoma. A randomized study. Proc ASCO 1986; 300: 77
   Google Scholar
• Vincent M D, Powles T J, Coombes R C, et al. Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer responding to conventional chemotherapy. Cancer Chemother Pharmacol 1988; 21: 255–60
   PubMed Web of Science ®Google Scholar
• Mouridsen H T, Rose C. Values and limitations of current criteria for objective response in advanced breast cancer. ESO monography. Endocrine therapy of breast cancer II, F Cavalli. Springer Verlag, Berlin 1987
   Google Scholar
• Davis H L, Multhauf P, Klotz J. Comparison of cooperative group evaluation criteria for multiple drug therapy for breast cancer. Cancer Treat Rep 1980; 64: 507–17
   Google Scholar
• Brunner K W. Evaluation criteria in comparative clinical trials in advanced breast cancer: a proposal for improvement. ESO Monography. Endocrine therapy of breast cancer II, F Cavalli. Springer Verlag, Berlin 1987
   Google Scholar
• Gelber R D, Goldhirsch A. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 1986; 4: 1772–9
   PubMed Web of Science ®Google Scholar